138 related articles for article (PubMed ID: 23407650)
1. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody.
Kasuya A; Hamaguchi Y; Fujimoto M; Tokura Y
Acta Derm Venereol; 2013 Nov; 93(6):715-6. PubMed ID: 23407650
[No Abstract] [Full Text] [Related]
2. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
[TBL] [Abstract][Full Text] [Related]
3. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
4. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
5. Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site.
Ohashi M; Shu E; Tokuzumi M; Fujioka K; Ishizuka T; Hara A; Fujimoto M; Kaji K; Seishima M
Acta Derm Venereol; 2011 Jan; 91(1):84-5. PubMed ID: 21088812
[No Abstract] [Full Text] [Related]
6. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies.
Schiffmann ML; Warneke VS; Ehrchen J
J Dtsch Dermatol Ges; 2018 Jan; 16(1):76-78. PubMed ID: 29232033
[No Abstract] [Full Text] [Related]
7. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
8. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
9. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
10. Vesiculo-bullous dermatomyositis: report of three cases.
Nishigori K; Yamamoto T; Yokozeki H
Dermatol Online J; 2009 Apr; 15(4):6. PubMed ID: 19450399
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
12. A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Targoff IN; Mamyrova G; Trieu EP; Perurena O; Koneru B; O'Hanlon TP; Miller FW; Rider LG; ;
Arthritis Rheum; 2006 Nov; 54(11):3682-9. PubMed ID: 17075819
[TBL] [Abstract][Full Text] [Related]
13. Dermatomyositis with elevated serum hyaluronate.
Kubo M; Ihn H; Matsukawa A; Kikuchi K; Tamaki K
Clin Exp Dermatol; 1999 Jul; 24(4):275-8. PubMed ID: 10457129
[TBL] [Abstract][Full Text] [Related]
14. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
[TBL] [Abstract][Full Text] [Related]
15. Malignancy and myositis: novel autoantibodies and new insights.
Selva-O'Callaghan A; Trallero-Araguás E; Grau-Junyent JM; Labrador-Horrillo M
Curr Opin Rheumatol; 2010 Nov; 22(6):627-32. PubMed ID: 20827204
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
17. Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy.
Saito W; Kase S; Yoshida K; Ohguro H; Yokoi M; Iwaki H; Ohno S
Am J Ophthalmol; 2005 Nov; 140(5):942-5. PubMed ID: 16310487
[TBL] [Abstract][Full Text] [Related]
18. Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia.
Ramírez-Bellver JL; Macías E; Bernárdez C; López-Robles J; Vegas-Sánchez MD; Díaz-Recuero JL; Quiceno H; Requena L
Am J Dermatopathol; 2017 Jan; 39(1):e3-e7. PubMed ID: 28045754
[TBL] [Abstract][Full Text] [Related]
19. Longlasting remissions after treatment with rituximab for autoimmune myositis.
Feist E; Dörner T; Sörensen H; Burmester GR
J Rheumatol; 2008 Jun; 35(6):1230-2. PubMed ID: 18528957
[No Abstract] [Full Text] [Related]
20. Ovoid palatal patch: a clue to anti-TIF1γ dermatomyositis.
Franciosi E; Blankenship K; Houk L; Rashighi M
BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32332045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
